血脂和TG/HDL-C水平与冠状动脉病变程度关系研究

目的研究血脂和甘油三酯/高密度脂蛋白胆固醇(TG/HDL-C)比值与冠状动脉病变程度的关系。方法128例选择性冠状动脉造影以计分法评定其病变程度,并评定各组患者血脂及有关比值之间的差异及其与冠状动脉病变程度之间的相互关系。结果血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、TG/HDL-C水平在重度病变组显著增高(P值分别小于0.01、0.05、0.05)。它们与冠状动脉病变程度分值之间的相关系数分别为0.20、0.14、0.41。结论TC和TG/HDL-C比值不仅和冠状动脉粥样硬化性心脏病(CHD)的发病相关,而且与冠状动脉病变程度相关。     

冠心病危险因素与冠状动脉病变的相关性分析

目的探讨冠心病危险因素与冠状动脉病变的相关性。方法回顾性分析我院行选择性冠状动脉造影检查(coronary angiography,CAG)337例的临床资料,设计调查表调查相关指标,依据CAG结果将其分为冠心病组和非冠心病组进行比较,分析冠心病危险因素与冠状动脉病变的关系,采用多因素Logistic回归分析筛选冠心病独立相关危险因素。结果两组血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血清总胆红素(TBIL)、血尿酸(UA)、空腹血糖(FBG)、纤维蛋白原(FIB)水平比较差异有统计学意义(P<0.05或P<0.01),MPV比较差异无统计学意义(P>0.05);随着男性比例、高血压、高血脂、吸烟、糖尿病等单个危险因素及年龄、血TC、LDL-C、FBG、FIB增加,血HDL-C、TBIL降低,冠状动脉病变支数、狭窄程度逐渐增加,差异有统计学意义(P<0.05),TG、UA与冠状动脉病变支数及狭窄程度无明显关系,差异无统计学意义(P>0.05);冠状动脉病变支数、病变积分与男性比例、高血压、糖尿病、吸烟、TC、LDL-C、FBG、FIB呈正相关(...     

冠状动脉粥样硬化与血脂代谢紊乱的因素分析

目的:探讨血脂代谢紊乱与冠状动脉粥样硬化之间的关系。方法:收集我院心内科住院前1个月内未服用降脂药且行冠状动脉造影患者共407例,冠状动脉狭窄≥50%者为冠心病组,无狭窄者为非冠心病组。冠心病组根据管腔受累内径、主要血管受累支数、病变损害程度进行评分。取患者空腹12h静脉血送检,将有无冠心病和冠脉病变程度、范围、积分与各项血脂指标进行相关分析。结果:冠心病组三酰甘油(TG)、载脂蛋白B(apoB)、脂蛋白a[LP(a)]致动脉硬化指数[log(TG/HDL-C)]、非高密度脂蛋白(NHDL)、脂蛋白a/高密度脂蛋白胆固醇[LP(a)/HDL-C]高于非冠心病组(P<0.05或P<0.01),血浆HDL-C、载脂蛋白A(1apoA1)低于非冠心病组(均P<0.05)。冠状动脉病变程度、范围、病变血管积分与患者的血浆LP(a)、NHDL、log(TG/HDL-C)、LP(a)/HDL-C比值呈正相关,与HDL-C呈负相关。对与病变血管积分相关的血脂指标与病变血管积分进行线性回归分析,与NHDL、log(TG/HDL-C)相比,LP(a)/HDL-C比值的增加,对病变积分影响最大。结论:血浆NHDL、log(TG/...     

空腹血糖与青年男性冠心病患者冠状动脉病变的关系

目的 探讨青年男性冠心病患者空腹血糖水平与冠状动脉病变程度的关系.方法 回顾性分析2009年1月至2010年12月于我院住院诊断为冠心病并行冠状动脉造影手术的青年男性(年龄≤44岁)共372例,根据冠状动脉造影结果,分为单支病变组(218例),双支病变组(84例)和三支病变组(70例),观察BMI、SBP、DBP、Hb、BUN、肌酐、血清尿酸、空腹血糖、TG、TC、HDL-C和LDL-C与冠状动脉病变程度的关系.结果 在单支病变、双支病变和三支病变组,空腹血糖水平逐渐升高,两两比较差异有统计学意义[分别为(6.4±2.1)、(7.5±2.5)和(8.4±3.4) mmol/L,均P＜0.05].SBP、TG、TC及HDL-C在单支病变组与其他2组比较存在统计学差异(均P＜0.05);LDL-C在单支病变组与双支病变组比较存在统计学差异(P＜0.05).Logistic回归分析显示,影响冠状动脉多支病变的独立危险因素为TG[4.381(1.221～15.727)]、空腹血糖[1.234(1.117 ～ 1.364)]及SBP[1.035(1.014～1.056)](均P＜0.05).结论 空腹血糖是青年男性冠心病患者冠状动脉多支病变的独立危险因素.     

总胆固醇与高密度脂蛋白胆固醇比值预测冠心病危险性的临床评价

目的评价总胆固醇与高密度脂蛋白胆固醇比值预测冠心病危险性的价值.方法冠心病患者117例列入冠心病组,健康人100例列入对照组,测定两组的TC/HDL-C、TC、TG、HDL-C和LDL-C并比较其差异性和异常率.结果冠心病组与对照组的单项血脂指标对比有显著性差异,TC/HDL-C有高度显著性差异（P＜0.01）,冠心病组TC/HDL-C异常率明显高于对照组（x^2=18.68,OR值=3.375）,也较其它单项血脂指标高,TC、TG、LDL-C和HDL-C的OR值分别为1.646、1.678、2.441和2.186.结论总胆固醇与高密度脂蛋白胆固醇比值作为冠心病危险因素的预测价值和灵敏度高于单项血脂指标.     

非高密度脂蛋白胆固醇及其与高密度脂蛋白胆固醇比值和2型糖尿病早期肾病的相关性分析

目的探讨非高密度脂蛋白胆固醇及其与高密度脂蛋白胆固醇比值与2型糖尿病早期肾病的相关性。方法选择我院收治的首次诊断为2型糖尿病患者共582例,根据患者24h尿微量白蛋白检测结果(MAU),将患者分为早期肾病组患者127例、非肾病组患者455例,比较两组患者空腹血糖值(FBG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、三酰甘油(TG)、总胆固醇(TC)。结果早期肾病组患者其FBG、LDL-C、TG、TC、non-.HDL-C以及non-HDL-C/HDL-C均显著高于非肾病组患者(P<0.05);而早期肾病组HDL-C显著低于非肾病组患者(P<0.05);经相关性分析显示,患者MAU与TG、TC、LDL-C、non-HDL-C以及non-HDL-C/HDL-C呈显著正相关关系(P<0.05);logistic回归分析显示non-HDL-C/HDL-C是2型糖尿病早期肾病独立危险因素。结论非高密度脂蛋白胆固醇及其与高密度脂蛋白胆固醇比值与2型糖尿病患者尿微量白蛋白之间呈显著正相关关系,且为2型糖尿病患者发生早期肾病的独立危险因素,对于非高密度脂蛋白胆固醇及其与高密度脂蛋白胆固醇比值检测有助于对2型糖尿病患者早期肾病的诊断以及防治。     

纤维蛋白原和血脂含量与冠状动脉病变的关系

目的：探讨纤维蛋白原（fibrinogen,FIB）与冠状动脉病变程度的相关性。方法：根据冠状动脉造影（coronary angiography,CAG）结果将326例疑诊冠状动脉粥样硬化性心脏病（简称冠心病）患者,根据狭窄血管支数分成单支、两支和三支组和对照组,术前检测血清FIB和血脂。比较FIB浓度在不同冠状动脉病变血管支数组间有无差异,FIB浓度与血脂进行相关分析并与冠脉病变血管支数进行多元逐步回归分析。结果：冠心病各组与对照组FIB浓度比较均有明显差异（P〈0.05或0.01）;FIB与HDL-C、ApoAI、TG、LDL-C、TC和ApoB明显相关（P〈0.05）;偏相关分析发现FIB浓度与冠状动脉病变血管支数明显相关（P〈0.01）。结论：FIB浓度与冠状动脉病变的严重程度相关。     

老年高血压患者胆红素、血脂水平与冠状动脉病变严重程度的相关性分析

目的探讨老年高血压患者冠状动脉病变程度与胆红素、血脂水平的关系。方法选取217例老年高血压患者,将冠状动脉主要血管或分支狭窄≥50%的患者165例作为观察组,狭窄〈50%患者52例作为对照组。观察组按病变支数分为单支病变、双支病变、多支病变亚组（分别为47、41、77例）。比较各组胆红素、血脂等生化指标差异及Gensini评分。结果观察组高密度脂蛋白胆固醇（HDL-C）及血胆红素水平明显低于对照组,三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平显著高于对照组,差异均有统计学意义（P〈0.05）;双支及多支病变亚组TG高于单支病变亚组及对照组,单支及多支病变亚组LDL-C水平高于对照组,双支病变亚组低于单支病变亚组,多支病变亚组高于单支及双支病变亚组,单支及多支病变亚组HDL-C水平低于对照组,且多支病变亚组低于双支病变亚组,双支及多支病变亚组血胆红素水平明显低于单支病变亚组和对照组,多支病变亚组低于双支病变亚组,差异均有统计学意义（P〈0.05）;单支、双支及多支病变亚组Gensini评分高于对照组,且积分随冠状动脉病变程度的加重而增高,差异均有统计学意义（P〈0.01）。冠心病患者Gensini评分与胆红素水平呈明显负相关（r=-0.161～-0.400,P〈0.01～0.05）。结论胆红素水平生理范围内增高是延缓老年高血压病发展为冠心病的保护因素,与冠状动脉病变程度呈负相关;早期干预胆红素水平有可能延缓老年高血压的发展并改善其预后。     

老年冠心病患者血脂代谢特点分析

目的:探讨老年冠心病患者血脂代谢特点。方法:选择784例65岁以上老年患者,根据冠状动脉造影所示病变支数及有无高血压、糖尿病进行分组,比较各项血脂指标(包括单项血脂和血脂比值)。结果:将所有研究对象根据冠脉病变支数分成4组后比较,载脂蛋白(Apo)B、总胆固醇(TC)/高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)/HDL-C、HDL-C和ApoA1/B水平在4组之间差异有统计学意义(P<0.01)。高血压组三酰甘油(TG)和ApoB水平升高,ApoA1/B水平下降(P<0.05)。糖尿病组TG和TC/HDL-C水平升高,HDL-C水平下降(P<0.05)。多元Logistic逐步回归分析表明ApoA1/B是冠心病的危险因素。结论:血脂比值对于冠心病的发生及严重程度具有一定的临床预测价值。高血压、糖尿病均影响血脂代谢,治疗老年冠心病患者需控制多重危险因素。     

冠状动脉狭窄患者的血脂水平临床分析

目的 探讨血脂水平与冠状动脉狭窄程度的关系.方法共收集我院362例行冠状动脉造影术的患者,进行临床生化指标检测.使用美国BECKMAN DxC800全自动生化分析仪进行.血清TG、TC用过氧化物酶法检测,HDL-C及LDL-C用直接法检测,载脂蛋白A1及载脂蛋白B用免疫透射比浊法测定.用冠状动脉病变支数表示冠状动脉病变严重程度,分析患者血脂水平及其比值与冠状动脉狭窄的关系.结果多因素回归分析显示,年龄、非HDL-C(N-HDL-C)、LDL-C/HDL-C、TC/HDL-C与冠状动脉病变支数成正相关.结论 受检者的血脂水平与其冠状动脉狭窄程度密切相关,以N-HDL-C、LDL-C/HDL-C、和ApoA1对冠状动脉狭窄的预测性更强.     

胆固醇/高密度脂蛋白-胆固醇比值在脑梗死中的价值研究

目的:探讨胆固醇/高密度脂蛋白-胆固醇比值(TC/HDL-C比值)与脑梗死发病危险性的关系以及这一比值在脑梗死患者合并高血压或糖尿病时的变化。方法:选择197例脑梗死患者分为三组:单纯脑梗死组、合并高血压组、合并糖尿病组。58例健康者作为正常对照组,探讨这一比值的变化。结果:胆固醇(TC)水平及TC/HDL-C比值在脑梗死患者与正常对照组间有显著性差异(P<0.05);脑梗死患者的HDL-C水平较正常对照组降低,但两者差异无显著性(P>0.05);不同病例组间TC、HDL-C水平及TC/HDL-C比值无显著性差异(P>0.05)。结论:TC/HDL-C比值是脑梗死的危险因素,与高血压、糖尿病无关。     

TC/GLU和LDL-C/HDL-C比值与结直肠息肉的相关性研究

目的:研究总胆固醇与空腹血糖比值(TC/GLU)和低密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值(LDL-C/HDL-C)对结直肠息肉的预测价值.方法:选取2017年2月至2018年12月在江苏省人民医院经肠镜检查的消化内科患者共2150例,收集患者肠镜前空腹静脉血中的TC、HDL-C、LDL-C、甘油三酯(TG)、GLU...     

Beyond LDL-C--the importance of raising HDL-C

Epidemiological studies have established that low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk of coronary heart disease (CHD). Recent studies have demonstrated that low HDL-C levels, and high triglycerides and total cholesterol levels are independent predictors of CHD, and that the combination of these lipid abnormalities increases the risk of coronary events. In lipid-modifying intervention studies, agents that raise HDL-C levels have been shown to reduce the incidence of major coronary events. The VA-HIT study consisted of patients with low-density lipoprotein cholesterol (LDL-C) levels similar to those recommended by several guidelines but with low levels of HDL-C. This trial demonstrated that raising HDL-C levels with gemfibrozil reduced the risk of CHD-related events. While the mechanisms by which HDL-C exerts its anti-atherogenic effects have yet to be fully elucidated, its role in the reverse transport of cholesterol and the beneficial effects on endothelial function are plausible explanations for these actions. Although LDL-C reduction is the primary goal in the treatment of dyslipidaemia, current guidelines recognise low HDL-C levels as a major risk factor for CHD. Indeed, the NCEP ATP III guidelines suggest that the treatment of isolated low HDL-C levels in CHD patients or individuals with CHD risk equivalents should be considered. The differing abilities of statins to raise HDL-C levels may be an important factor when making treatment decisions. New lipid-modifying drugs with beneficial effects on both HDL-C and LDL-C levels would be desirable additions to the currently available therapeutic options.     

HDL-C低下原因及影响因素

血浆 HDL- C水平与冠心病的发生率呈显著的负相关 ,血浆 HDL- C水平低下与过早发生的冠心病 (年龄≤ 5 5岁 )之间有明显的相关性。引发 HDL- C水平低下的原因有 :1　遗传 :家族性低 α-脂蛋白血症系常染色体显性遗传 ,其主要特重是血浆 HDL- C水平低于年龄、性别相匹配对照者的第10百分位值。2　高甘油三酯血症 :该症患者常有 HDL- C水平降低 ,据认为影响因素主要是 CETP和 L CAT的平衡被打乱 ,表现为ECTP活性升高 ,L CAT活性降低 ,二者共同作用 ,可使 HDL-C水平变异达 2 5 %。3　药物 :一些药物可改变血浆 HDL- C浓度 ,…     

Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C

OBJECTIVE: To evaluate the efficacy of high and moderate doses of simvastatin (80 and 40 mg), for raising high density lipoprotein-cholesterol (HDL-C), improving HDL sub-fractions, and affecting other parameters, including high sensitivity C-reactive protein (hs-CRP), in patients with type 2 diabetes mellitus (DM) and low HDL-C. RESEARCH DESIGN AND METHODS: This double-blind, placebo-controlled, randomized, 3-period, complete block, 6-week crossover study examined the efficacy of simvastatin in adult men and women (N = 151) with stable type 2 DM (HbA(1C) < 9%), low density lipoprotein-cholesterol (LDL-C) > 100 mg/dL (2.6 mmol/L), HDL-C < 40 mg/dL (< 1 mmol/L), and fasting triglyceride level > 150 (> 1.7 mmol/L) and < 700 mg/dL (< 7.9 mmol/L). This study included adult men (71%) and women (29%) of various races (89% white, 6% black, 1% Asian, 3% other) enrolled from 29 practice-based sites in the United States. MAIN OUTCOME MEASURES: Percentage change in HDL-C from baseline at the end of each 6-week treatment interval. RESULTS: Both simvastatin 80 and 40 mg significantly increased total HDL-C from baseline (mean increases of 8% +/- 1 [SE] and 5% +/- 1, respectively; p < 0.001) compared with placebo, and significantly reduced plasma concentrations of LDL-C (p < 0.001), triglycerides (p < 0.001), apolipoprotein B (p < 0.001), and hs-CRP (p < or = 0.012). Compared with simvastatin 40 mg, the 80 mg dose provided additional efficacy. Simvastatin 80 mg also significantly (p < 0.001) increased HDL(2) from baseline (14% +/- 3[SE]) and placebo phases (10 +/- 3). An exploratory analysis showed 87% (simvastatin 80 mg) and 82% (simvastatin 40 mg) of patients reached the NCEP ATP III treatment goals for LDL-C compared with 14% on placebo. CONCLUSIONS: Both simvastatin 80 and 40 mg raise HDL-C and improve other measures associated with elevated coronary risk in patients with type 2 DM and low HDL-C.     

Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C

SUMMARY

Objective: To evaluate the efficacy of high and moderate doses of simvastatin (80 and 40?mg), for raising high density lipoprotein-cholesterol (HDL-C), improving HDL sub-fractions, and affecting other parameters, including high sensitivity C-reactive protein (hs-CRP), in patients with type 2 diabetes mellitus (DM) and low HDL-C.

Research design and methods: This double-blind, placebo-controlled, randomized, 3-period, complete block, 6-week crossover study examined the efficacy of simvastatin in adult men and women (N = 151) with stable type 2 DM (HbA_1C < 9%), low density lipoprotein-cholesterol (LDL-C) > 100?mg/dL (2.6?mmol/L), HDL-C < 40?mg/dL (< 1?mmol/L), and fasting triglyceride level > 150 (> 1.7?mmol/L) and < 700?mg/dL (< 7.9?mmol/L). This study included adult men (71%) and women (29%) of various races (89% white, 6% black, 1% Asian, 3% other) enrolled from 29 practice-based sites in the United States.

Main outcome measures: Percentage change in HDL-C from baseline at the end of each 6-week treatment interval.

Results: Both simvastatin 80 and 40?mg significantly increased total HDL-C from baseline (mean increases of 8% ± 1 [SE] and 5% ± 1, respectively; p < 0.001) compared with placebo, and significantly reduced plasma concentrations of LDL-C (?p < 0.001), triglycerides (?p < 0.001), apolipoprotein B (?p < 0.001), and hs-CRP (?p ≤ 0.012). Compared with simvastatin 40?mg, the 80?mg dose provided additional efficacy. Simvastatin 80?mg also significantly (?p < 0.001) increased HDL₂ from baseline (14% ± 3[SE]) and placebo phases (10 ± 3). An exploratory analysis showed 87% (simvastatin 80?mg) and 82% (simvastatin 40?mg) of patients reached the NCEP ATP III treatment goals for LDL-C compared with 14% on placebo.

Conclusions: Both simvastatin 80 and 40?mg raise HDL-C and improve other measures associated with elevated coronary risk in patients with type 2 DM and low HDL-C.     

LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study

BACKGROUND: The ratio of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (LDL-C/HDL-C) is a reliable predictor of cardiovascular risk. Low HDL-C levels in patients with coronary artery disease are associated with a high risk for cardiovascular events. OBJECTIVES: This study compared the effects of rosuvastatin and atorvastatin on the LDL-C/HDL-C. METHODS: Patients aged 40-80 years with established cardiovascular disease and HDL-C < 1.0 mmol/L (< 40 mg/dL) entered as a 6-week dietary run-in period, before randomisation to open-label treatment with rosuvastatin 10 mg (n = 230) or atorvastatin 20 mg (n = 231) for 6 weeks. Doses were increased after 6 weeks to rosuvastatin 20 mg or atorvastatin 40 mg, and after 12 weeks to rosuvastatin 40 mg or atorvastatin 80 mg. Serum lipid parameters were measured at baseline and 6, 12 and 18 weeks. RESULTS: After 6 weeks of treatment, mean percentage change from baseline in LDL-C/HDL-C ratio was -47.0% in the rosuvastatin group and -41.9% in the atorvastatin group (p < 0.05 for between-group comparison). After 12 and 18 weeks of treatment, change from baseline was -53.0% and -57.3%, respectively, for rosucastatin, compared with -47.9% and -49.6%, respectively, for atorvastatin (p < 0.01 and p < 0.001, respectively, for between-group comparison). Rosuvastatin also reduced LDL-C, total cholesterol/HDL-C significantly more than atorvastatin at all three time points, and significantly improved total cholesterol/HDL-C and apolipoprotein B/A-I ratios. CONCLUSIONS: Rosuvastatin 10, 20 and 40 mg is significantly more effective than atorvastatin 20, 40 and 80 mg, respectively, in improving the LDL-C/HDL-C ratio in patients with cardiovascular disease and low HDL-C. Further studies are required to clarify the benefits of rosuvastatin for reduction of cardiovascular risk.     

高密度脂蛋白胆固醇与老年心脑血管疾病的关系

目的探讨高密度脂蛋白胆固醇与老年心脑血管疾病的联系。方法对入住笔者所在医院的93名老年心脑血管患者和90名老年健康体检者进行高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、总胆固醇、甘油三脂的检测比较,并对HDL-C进行分段分组比较。结果老年心脑血管患者的LDL-C、TC、TG水平明显高于老年健康体检者(P0.05),HDL-C的水平明显低于老年健康体检者(P0.05)。结论 HDL-C的水平与老年心脑血管疾病发生有密切关系,且HDL-C水平越低,心脑血管疾病的发生率越高。     

急性冠状动脉综合征严重程度与血清HDL-C/LDL-C比值相关性的研究

目的：探讨急性冠状动脉综合征（ACS）患者血清HDL-C/LDL-C比值与疾病严重程度的相关性,观察分析HDL-C/LDL-C比值是否可作为判断ACS疾病严重程度的客观生化指标。方法：入选的382例受试对象,分为对照组（n=156）,稳定型心绞痛（SA）组（n=89）,不稳定性心绞痛（UA）组（n=78）和急性心肌梗死（AMI）组（n=59）,并对UA患者进行Braunwald分级,对AMI患者进行Killip分级。采集受试者清晨空腹血液标本,采用消除法测定血清HDL-C、LDL-C、CK-MB并计算HDL-C/LDL-C比值。用SPSS软件包进行统计学分析。结果：ACS患者血清HDL-C/LDL-C比值与疾病严重程度存在良好的相关性：随着Braunwald分级增高,UA患者血清HDL-C/LDL-C比值逐渐降低（三级之间及每两级之间的HDL-C/LDL-C比值的差异均有统计学意义,P〈0.05）;随着Killip分级增高,AMI患者血清HDL-C/LDL-C比值也逐渐降低（三级之间及每两级之间的HDL-C/LDL-C比值的差异均有统计学意义,P〈0.05）。血清HDL-C/LDL-C比值ACS患者明显低于SA患者（P〈0.05）。结论：ACS患者血清HDL-C/LDL-C比值与疾病的严重程度有良好的相关性,HDL-C/LDL-C比值可能会成为判断ACS疾病严重程度的客观生化指标之一。